Home/Pipeline/Lorigerlimab (MGD019)

Lorigerlimab (MGD019)

Advanced Solid Tumors, Prostate Cancer (PROC/CCGC)

Phase 2Active (LINNET Study)NCT06730347

Key Facts

Indication
Advanced Solid Tumors, Prostate Cancer (PROC/CCGC)
Phase
Phase 2
Status
Active (LINNET Study)
Company

About MacroGenics

MacroGenics is a fully-integrated biopharmaceutical company with a mission to develop and commercialize life-changing, antibody-based cancer medicines. Its strategy is built upon a suite of proprietary technology platforms that generate a diverse pipeline of novel bispecific antibodies and ADCs, both for proprietary development and strategic partnerships. The company has advanced multiple candidates into clinical trials, retains economic rights to several partnered/commercialized assets, and maintains in-house GMP manufacturing capabilities to control its development destiny.

View full company profile

About MacroGenics

MacroGenics is a fully-integrated biopharmaceutical company with a mission to develop and commercialize life-changing, antibody-based cancer medicines. Its strategy is built upon a suite of proprietary technology platforms that generate a diverse pipeline of novel bispecific antibodies and ADCs, both for proprietary development and strategic partnerships. The company has advanced multiple candidates into clinical trials, retains economic rights to several partnered/commercialized assets, and maintains in-house GMP manufacturing capabilities to control its development destiny.

View full company profile

Therapeutic Areas